ACST stock: buy or sell?
January 17th, 2020
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases.
Should I buy ACST stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. That's why is so important to define your own trading strategy that matches with your character as inversor. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with Acasti Pharma stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Acasti Pharma stock a buy?
Banks and financial institutions post stock ratings everyday.At Stocks2.com, we gathered 6 ratings published for ACST stock in the last 30 days. The general sentiment of these ratings is bullish for ACST stock, with 6 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
ACST stock analysis
Acasti Pharma shares plummed -4.88% to $0.78 yesterday.
Acasti Pharma ended yesterday at $0.78 and plummed a spooky -4.88%. In the last 5 days when ACST stock price broke down the SMA200d line, it slid $-1.40 per share (-64.22%). Since SMA50d and SMA100d crossed up on Dec/20, ACST price slid a -69.53%.
Shares of Acasti Pharma closed this week at $0.78 and collapsed a scary -64.22%. By mid December 2019 ACST rocketed an astounding 28.92% in just one week. Counting this, it's been 4 sliding weeks in a row, loosing $-2.09 (-102.45%).
The support didn't resisted and ACST sinked deeper. Possible next supports for ACST stock are 0.76. This week, Acasti Pharma stock dived below the significant level of the 40-weeks moving average. Stocks under the 40-weeks moving average line are usually not recommended for average traders. Since SMA10w and SMA20w crossed up by mid December 2019, ACST price slid a -61.76%.
ACST stock price history
ACST IPO was on June 6th, 2012 at $20.00 per share1. Since then, ACST stock declined a -96.10%, with a yearly average of -13.70%.
1: Adjusted price after possible price splits or reverse-splits.
ACST stock historical price chart
ACST stock reached 52-week highs on December/23 at $3.08, and all-time highs 2013-07-24 with a price of 42.
ACST stock price target is $6.90Nobody can reliably foresee how stock prices may evolve in the future. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we found 4 price targets for Acasti Pharma stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, Acasti Pharma didn't meet the expectations of the analysts and reported a hair-raising EPS of $-0.05 per share when experts were expecting $-0.08.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2014, last anual turnover report draw a chilling decrease of -45.97% to $0.27 M USD. When comparing 2015 vs 2014, instead, profit margin (that is, the net income divided by revenues) boosted a 1,706.37% to -611.57%.
|2013||$0.72 M||-||$-6.89 M-951.4%||-|
|2014||$0.50 M||-30.84%||$-11.61 M-2317.9%||68.51%|
|2015||$0.27 M||-45.97%||$-1.66 M-611.6%||-85.75%|
Quarterly financial resultsReported quarter income marked $-4.61 million with a profit margin of . Profit margin stayed stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing turnover to same quarter last year, Acasti Pharma sales marked a tight movement and remained constant a nan%. Looking back to recent quarterly results, Acasti Pharma posted 6 negative quarters in a row.
Acasti Pharma ownershipWhen you are planning to buy shares of a company, it's always worth to overview its ownership structure.
Acasti Pharma shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 15.55% of all shares.
In case of Acasti Pharma stock, 4.60% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for ACST stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Acasti Pharma:
|Market cap||$68.6 M||$678.6 M|
|Total shares||88.0 M||49.8 M|
|Float shares||72.0 M||44.5 M|
|- Institutional holdings (%)||4.6%||48.7%|
|- Insider holdings (%)||15.6%||5.4%|
|Shares in short selling||0.0%||0.0%|
|Friday, January 17th, 2020|
|Day range||$0.77 - $0.81|
|Average true range||$0.30|
|50d mov avg||$2.00|
|100d mov avg||$2.00|
|200d mov avg||$1.65|
Acasti Pharma performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We compared Acasti Pharma against Array in the following table: